US Food and Drug Administration

Pfizer Announces IBRANCE Clinical Trials Ended Early In Light of Promising News

In light of promising results conducted by an independent data monitoring committee, Pfizer’s newest treatment IBRANCE (Palbociclib) ended clinical trials early this week as phase 3 of the trials ended demonstrating improvement in progression-free survival in women who had undergone treatment for metastatic breast cancer.

FDA Issues Warning for the Quit-Smoking Drug Chantix

Chantix has helped many people quit smoking in the years since its release. However, on Monday the U.S. Food and Drug Administration issued a warning about the quit-smoking drug made by Pfizer Inc. According to the FDA, the drug has been associated with seizures and that some patients who drink while taking the drug may become aggressive or even black out.

E-cigarettes Lure the Young Into Tobacco Smoking: Study

With the publicity that e-cigarettes are the safer alternative for the more health hazardous tobacco products, more people resort to e-cigarettes (also referred to as e-cigs) and the younger generation have been drawn to the "cooler and hipper" e-cigarettes with their attractive packaging and fruity taste. However, a recent study found that e-cigarette smoking increased the likelihood among youngsters to smoke the nicotine-rich cigarette.

Recommended Stories

Real Time Analytics